News Suven Life Sciences Limited

Equities

SUVEN

INE495B01038

Delayed Bombay S.E. Other stock markets 05:14:22 2024-05-21 am EDT			5-day change	1st Jan Change
99.3 ^INR	-1.19%		-1.00%	+23.11%

May. 06	Suven Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
May. 06	Suven Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Suven Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 06	CI
Suven Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 06	CI
Suven Life Sciences to Present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology 2024 Annual Meeting, Denver, USA	Apr. 15	CI
Suven Life Sciences Announces Randomization of First Patient in Phase-2 POC Clinical Trial of Ropanicant (SUVN-911) for the Treatment of Moderate to Severe Major Depressive Disorder Study in USA	Feb. 06	CI
Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024	Jan. 30	CI
Suven Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 30	CI
Suven Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 04	CI
Suven Life Sciences : October 30, 2023Suven Life Sciences announces Positive Topline Results from a Phase-2 study evaluating Samelisant	23-10-30	PU
Suven Life Sciences Announces Positive Topline Results from A Phase-2 Study Evaluating Samelisant (SUVN-G3031) for Excessive Daytime Sleepiness in Adult Narcolepsy Patients with and Without Cataplexy	23-10-30	CI
October 24, 2023Suven Life Sciences Announces Scientific Presentation at CTAD-2023: Study Design of Global Phase-3	23-10-24	PU
Suven Pharma Appoints New Board and Management Team	23-09-29	CI
Suven Pharma Appoints Sudhir Kumar Singh as CEO	23-09-29	CI
Transcript : Suven Life Sciences Limited, Q1 2024 Earnings Call, Aug 10, 2023	23-08-10
Suven Life Sciences Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-08	CI
Suven Life Sciences : July 17, 2023Suven Life Announces Clinical and Preclinical data Poster Presentations at AAIC 2023, Amsterdam.	23-07-17	PU
Suven Life Sciences : Form MGT-7 FY 2022-23	23-07-15	PU
Suven Life Sciences : Annual Report FY 2022-23 (Book)	23-07-12	PU
Suven Life Sciences : Annual Report 2022-2023	23-07-12	PU
Suven Life Sciences announces two poster presentations including patient baseline characteristics and demographics from the phase-2 Proof of Concept study on samelisant at the SLEEP-2023 annual meeting	23-06-05	AQ
Suven Life Sciences : June 03, 2023Suven announces two poster presentations from the phase-2 (PoC) study on samelisant (SUVN-G3031)	23-06-03	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Suven Life Sciences Limited

Equities

SUVEN

INE495B01038

Summary

Filters